Neuralink Secures $600 Million in Funding, Reaching $9 Billion Valuation Amid FDA Progress

Neuralink, the brain-computer interface startup founded by Elon Musk, has successfully raised $600 million in a new funding round, pushing its pre-money valuation to $9 billion, according to reports from Semafor. The identities of the investors involved in this round were not disclosed. This significant capital infusion follows Neuralink’s previous fundraising of $43 million in November 2023, when the company was valued at approximately $5 billion. The rapid increase in valuation highlights growing investor confidence in Neuralink’s technological advancements and market potential.

In recent months, Neuralink has made notable regulatory progress, having received ‘breakthrough device’ designation from the U.S. Food and Drug Administration (FDA) last year. This status is granted to devices that offer significant advantages over existing options for treating or diagnosing life-threatening or irreversibly debilitating diseases or conditions. So far, three individuals have received Neuralink’s brain implants. Notably, a nonverbal patient recently demonstrated the practical impact of the technology by using his Neuralink implant to edit and narrate YouTube videos solely through brain signals.

The funding round aligns with earlier reports that Neuralink was seeking to raise between $500 million and $600 million at a valuation between $8.5 and $9 billion. The company’s progress in both clinical application and regulatory approval suggests that it is moving closer to commercializing its brain-computer interface technology.